Attard, Gerhardt

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 3,645

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,185

Abiraterone for prostate cancer not previously treated with hormone therapy

James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,801

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 903

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group

Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 783

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 605

Characterization of ERG , AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 533

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 394

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 268

Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?

Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 242

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

Attard, G., Belldegrun, A. S., & De Bono, J. S. (2005) · BJU International

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 207

Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer

Ferraldeschi, R., Sharifi, N., Auchus, R. J., & Attard, G. (2013) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 93

Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids

Attard, G., Reid, A. H. M., & de Bono, J. S. (2010) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 35

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Chi, K. N. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J. J., Gomes, A. J. P. D. S., Rathkopf, D., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 12

3381: Primary endpoint analysis of TRAP, first prospective Phase II trial of SBRT to oligoprogressive disease prostate cancer (NCT03644303)

Patel, P., Dreibe, S., Attard, G., Cole, A. J., Frew, J., Guevara, J., Mullassery, V., Murray, J., Parker, C., Palaniappan, N., et al. (2024) · Radiotherapy and Oncology

Prostate Cancer Diagnosis and TreatmentAdvanced Radiotherapy Techniques

Cited by 4